Clinical Trials Logo

Heart Failure With Reduced Ejection Fraction clinical trials

View clinical trials related to Heart Failure With Reduced Ejection Fraction.

Filter by:

NCT ID: NCT03359967 Not yet recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment

CHILISALT
Start date: February 12, 2018
Phase: N/A
Study type: Observational

The CHILISALT Study aimed to explore the effect of angiotensin-neprilysin inhibition on intrathoracic impedance and -derived fluid index in HFrEF patients who had a device for cardiac resynchronization therapy and/or an implantable cardioverter-deļ¬brillator (ICD; Medtronic Inc., Minneapolis, MN) allowing continuous measurement of intrathoracic impedance.

NCT ID: NCT03345446 Recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Circulating RNAs in Acute Congestive Heart Failure

CRUCiAL
Start date: August 17, 2016
Phase: N/A
Study type: Observational

The purpose of this American Heart Association-funded and NIH-funded study is to examine circulating RNAs in the acute CHF setting, how they change with decongestive therapy, and their function in vitro and in vivo. The investigators are testing the hypothesis that ex-RNA levels change significantly during decongestion therapy and can be used as a marker of those individuals who respond to CHF therapy (in terms of cardiac structure or outcome). Additionally, the translational research design allows the investigators to assay the effects of these RNAs on tissue phenotypes in vitro.

NCT ID: NCT03334188 Not yet recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Electronic Health Record-leveraged, Patient-centered, Intensification of Chronic Care for HF

EPIC-HF
Start date: January 2018
Phase: N/A
Study type: Interventional

The EPIC-HF study will test the effectiveness of a patient empowerment and activation for optimization of Heart Failure with reduced Ejection Fraction (HFrEF) medication plans. Three main regional centers in the UCHealth system will participate in a two-arm, randomized study design. In this design, each site participates in both control and intervention, with members of the sites eligible patient population randomly enrolled in either the intervention or the control arm. All eligible patients who agree to participate in the study will complete the Baseline Survey, the Follow-Up Survey, and will have information collected from their medical record at baseline, 1 month after the first clinic appointment post-enrollment, and 1 year after enrollment. Sites will carry out enrollment and Baseline Surveys with patients; all other study procedures will be conducted by study personnel at the University of Colorado (UC) School of Medicine (SOM) (UCSOM). Patients enrolled in the intervention arm will receive, by email and/or text, a link to 1) a short patient engagement video around HFrEF medications, and 2) a link to an online PDF of a HFrEF medication checklist. Patients in the intervention arm will receive these materials after enrollment and one week prior to their next scheduled clinic appointment. The materials will be delivered in a second communication, three days after the first, via text, as well as a third communication on the day of the clinic appointment. Patients enrolled in the control arm will not receive any materials at any point of time and will receive their usual care. For both arms, medication changes in patient medical records will be assessed before and after clinic visits to measure the effectiveness of the intervention on aim 1; surveys will be compared before and after clinic visits to determine the effectiveness of the intervention on aim 2.

NCT ID: NCT03332888 Not yet recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Safety of HMA-CD20 in Patients With HFrEF

SACD20-HFrEF
Start date: January 15, 2018
Phase: Phase 2
Study type: Interventional

The study is a phase II single-centered, single group, prospective clinical trial to evaluate the safety of HMA-CD20 doses among stable patients with class III/IV according to the NYHA classification with HFrEF receiving standard of care therapy. The index qualifying HFrEF must have EF < 40% based on echocardiographic or cardiac MRI techniques, heart failure class III/IV according to the NYHA classification,aged 40-60 years, being diagnosed less than 12 months before enrollment of study, following the standard heart failure treatment regimen.

NCT ID: NCT03317314 Recruiting - Heart Failure Clinical Trials

Cardiopulmonary Interactions in Patients With Heart Failure

Start date: July 1, 2017
Phase: N/A
Study type: Observational

This study aims to evaluate cardiopulmonary interactions in patients with heat failure

NCT ID: NCT03289637 Not yet recruiting - Clinical trials for Vitamin D Deficiency

Supplementation With Vitamin D to Patients With Heart Failure (D-Heart).

D-Heart
Start date: October 1, 2017
Phase: N/A
Study type: Interventional

In 200 patients with documented systolic heart failure give supplementation with vitamin D in those with a 25-OH- vitamin D < 50nmol/L - or placebo. In those with a vitamin D level <25nmol/L a substitution of 2400IU will be given, and in those with a vitamin D level 25-50nmol/L a substitution of 1600IU will be given. Intervention time 12 months. Biomarkers of heart function, quality of life, and hospitalisation will be analysed.

NCT ID: NCT03235700 Recruiting - Clinical trials for Coronary Artery Disease

Hyperemic Efficacy of IV Adenosine in HFrEF

HF-FFR
Start date: March 1, 2017
Phase: N/A
Study type: Interventional

Little is known about the hyperemic efficacy of IV adenosine as well as safety in patients with heart failure with reduced ejection fraction (HFrEF) because they were excluded from the major FFR studies. We will evaluate the feasibility and hyperemic efficacy of IV adenosine in patients with HFrEF in comparison with IC nicorandil for invasive physiological assessment using a coronary pressure wire.

NCT ID: NCT03228030 Not yet recruiting - Heart Failure Clinical Trials

Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial

THIAMINE-HF
Start date: January 2018
Phase: Phase 3
Study type: Interventional

Heart failure (HF) is a major cardiovascular disease with increasing prevalence. Thiamine deficiency is common in HF patients. Previous small studies have shown that thiamine supplementation can improve left ventricular systolic function in HF, but larger clinical studies are lacking. Given the ease of supplementation and the potential benefits in HF, we aim to conduct a pilot randomized controlled trial (RCT) using high dose thiamine supplementation in HF patients. The main goal of this pilot study is to determine the feasibility of recruitment for an RCT of thiamine supplementation.

NCT ID: NCT03213821 Not yet recruiting - Renal Insufficiency Clinical Trials

Safety and Efficacy of High Protein Diet Versus GFR Based Protein Diet in Heart Failure Patients With Renal Insufficiency

GFR
Start date: November 1, 2017
Phase: N/A
Study type: Interventional

Effect of high calorie high protein diet versus high calorie,glomerular filtration rate (GFR) based protein intake in non-obese advanced HF patients will be assessed. In this regard, protein intake impact will be measured on muscle mass, physical performance and renal function as main outcome. Rehospitalization, quality of life, depression an inflammatory status are second endpoints.

NCT ID: NCT03209180 Recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Immediate Release Versus Slow Release Carvedilol in Heart Failure

SLOW-HF
Start date: October 27, 2016
Phase: Phase 4
Study type: Interventional

Assessment of clinical effect and treatment quality of immediate release carvedilol (IR) versus slow release carvedilol (SR) in patients with HFrEF